RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient

SIMPLE SUMMARY: We identified an acquired RAC1 (P34R) mutation in the metastatic tumor of a BRAF-mutated papillary thyroid cancer patient treated with the BRAF inhibitor dabrafenib. Further investigations uncovered a high RAC1 copy number in the metastatic sample and its derived cell line. We demons...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagheri-Yarmand, Rozita, Busaidy, Naifa L., McBeath, Elena, Danysh, Brian P., Evans, Kurt W., Moss, Tyler J., Akcakanat, Argun, Ng, Patrick K. S., Knippler, Christina M., Golden, Jalyn A., Williams, Michelle D., Multani, Asha S., Cabanillas, Maria E., Shaw, Kenna R., Meric-Bernstam, Funda, Shah, Manisha H., Ringel, Matthew D., Hofmann, Marie Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507731/
https://www.ncbi.nlm.nih.gov/pubmed/34638434
http://dx.doi.org/10.3390/cancers13194950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507731/
https://www.ncbi.nlm.nih.gov/pubmed/34638434
http://dx.doi.org/10.3390/cancers13194950

Ejemplares similares